Technical Analysis for SYBX - Synlogic, Inc.

Grade Last Price % Change Price Change
grade B 2.51 2.45% 0.06
SYBX closed up 2.45 percent on Friday, May 29, 2020, on 1.68 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical SYBX trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Overbought Stochastic Strength 0.00%
200 DMA Support Bullish 2.45%
Pocket Pivot Bullish Swing Setup 2.45%
Stochastic Reached Overbought Strength 2.45%
Outside Day Range Expansion 2.45%
Overbought Stochastic Strength 2.45%
Upper Bollinger Band Touch Strength 2.45%
200 DMA Support Bullish 2.87%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.
Cancer Biology Disease Diabetes Obesity Inflammatory Bowel Disease Inborn Errors Of Metabolism Phenylketonuria Rare Genetic Diseases Synthetic Biology Pku Intellectual Disability

Is SYBX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.01
52 Week Low 1.35
Average Volume 297,664
200-Day Moving Average 2.36
50-Day Moving Average 2.06
20-Day Moving Average 2.26
10-Day Moving Average 2.36
Average True Range 0.22
ADX 28.58
+DI 22.67
-DI 12.70
Chandelier Exit (Long, 3 ATRs ) 1.90
Chandelier Exit (Short, 3 ATRs ) 2.60
Upper Bollinger Band 2.53
Lower Bollinger Band 1.99
Percent B (%b) 0.96
BandWidth 24.07
MACD Line 0.11
MACD Signal Line 0.09
MACD Histogram 0.0198
Fundamentals Value
Market Cap 40.87 Million
Num Shares 16.3 Million
EPS -9.33
Price-to-Earnings (P/E) Ratio -0.27
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.86
Resistance 3 (R3) 2.82 2.67 2.80
Resistance 2 (R2) 2.67 2.58 2.69 2.78
Resistance 1 (R1) 2.59 2.53 2.63 2.63 2.76
Pivot Point 2.44 2.44 2.46 2.46 2.44
Support 1 (S1) 2.36 2.35 2.40 2.39 2.26
Support 2 (S2) 2.21 2.30 2.23 2.24
Support 3 (S3) 2.13 2.21 2.22
Support 4 (S4) 2.16